← Back to Screener
Candel Therapeutics, Inc. Common Stock (CADL)
Price$8.51
Value ScoreF
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)70.48%
Price vs S&P 500 (4W)1.93%
VGM Score50.03
Market Capitalization$623.53M
All Metrics
Book Value / Share (Quarterly)$1.88
P/TBV (Annual)0.59x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.67
Price vs S&P 500 (YTD)42.46%
Net Profit Margin (TTM)-15156.45%
EPS (TTM)$-0.98
10-Day Avg Trading Volume1.79M
EPS Excl Extra (TTM)$-0.98
EPS (Annual)$-1.74
ROI (Annual)-70.00%
Cash / Share (Quarterly)$2.66
ROA (Last FY)-51.63%
EBITD / Share (TTM)$-0.99
ROE (5Y Avg)-109.18%
Operating Margin (TTM)-28000.81%
Cash Flow / Share (Annual)$-0.71
P/B Ratio4.52x
P/B Ratio (Quarterly)2.60x
Net Income / Employee (Annual)$-1,003,200
EV / Revenue (TTM)3840.09x
Net Interest Coverage (TTM)-53.96x
ROA (TTM)-41.33%
EPS Incl Extra (Annual)$-1.74
Current Ratio (Annual)13.49x
Quick Ratio (Quarterly)27.63x
3-Month Avg Trading Volume1.63M
52-Week Price Return53.33%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.80
P/S Ratio (Annual)4988.24x
Asset Turnover (Annual)0.00x
52-Week High$9.57
EPS Excl Extra (Annual)$-1.74
CapEx CAGR (5Y)-16.84%
26-Week Price Return78.41%
Quick Ratio (Annual)13.31x
13-Week Price Return75.46%
Total Debt / Equity (Annual)0.91x
Current Ratio (Quarterly)28.05x
Enterprise Value$476.17M
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-15035.20%
Cash / Share (Annual)$2.18
3-Month Return Std Dev83.80%
Net Income / Employee (TTM)$-989,500
ROE (Last FY)-83.19%
Net Interest Coverage (Annual)-68.11x
EPS Basic Excl Extra (Annual)$-1.74
Total Debt / Equity (Quarterly)0.34x
EPS Incl Extra (TTM)$-0.98
ROI (TTM)-46.54%
P/S Ratio (TTM)5028.47x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.65
Price vs S&P 500 (52W)28.97%
Year-to-Date Return50.62%
5-Day Price Return0.00%
EPS Normalized (Annual)$-1.74
ROA (5Y Avg)-50.92%
Net Profit Margin (Annual)-15035.20%
Month-to-Date Return2.53%
Cash Flow / Share (TTM)$-1.07
EBITD / Share (Annual)$-1.02
Operating Margin (Annual)-27777.60%
LT Debt / Equity (Annual)0.91x
ROI (5Y Avg)-66.33%
LT Debt / Equity (Quarterly)0.34x
EPS Basic Excl Extra (TTM)$-0.98
P/TBV (Quarterly)1.23x
P/B Ratio (Annual)5.97x
Pretax Margin (TTM)-15156.45%
Book Value / Share (Annual)$0.95
Price vs S&P 500 (13W)67.21%
Beta-0.42x
Revenue / Share (TTM)$0.00
ROE (TTM)-60.42%
52-Week Low$4.35
vGradeF
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.14est. -0.32
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.13
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CADLCandel Therapeutics, Inc. Common Stock | F | — | A | $8.51 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Candel Therapeutics is a clinical-stage biopharmaceutical company developing viral immunotherapies designed to activate immune responses against cancer. The company operates two proprietary viral platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, positioning it in the emerging viral oncology sector.